

**AccuDiag™
 B2-Microglobulin
 ELISA Kit**

Cat# 4200-16



Test	Beta 2 -Microglobulin
Method	Enzyme Linked Immunosorbent ELISA
Principle	Peroxidase - Conjugated Competitive ELISA
Detection Range	0-20 µg/mL
Sample	10 µl serum
Specificity	96 %
Sensitivity	2.0 µg/mL
Total Time	~ 80 min
Shelf Life	12 -14 Months from the manufacturing date

INTENDED USE

The Beta-2 Microglobulin EIA Test is an enzyme immunoassay (EIA) for the measurement of Beta-2 Microglobulin in serum as an aid in the diagnosis of active rheumatoid arthritis and kidney disease.

SUMMARY AND EXPLANATION

Human Beta-2 Microglobulin (B2MG) is an 11.8 kD protein identical to the light chain of the HLA-A, -B, and -C antigen. B2MG is expressed on nucleated cells, and is found at low levels in the serum and urine of normal individuals. B2MG concentrations are increased in inflammatory diseases, some viral diseases, renal dysfunction, and autoimmune diseases. A number of publications are available which explain the interpretation of B2MG serum levels in assessing the status of individuals with various clinical conditions. The enzyme immunoassay allows the quantitative determination of B2MG from serum. In this assay, the B2MG in the samples is bound to an available excess of monoclonal antibodies against B2MG, which are immobilized to the surface of the microtiter wells. After a washing step to remove all foreign substances, the quantification of bound B2MG is carried out by adding an enzyme (horseradish peroxidase or HRPO) labeled antibody, which also binds to the B2MG. The amount of bound enzyme is directly proportional to the B2MG content. The substrate is then converted to a chromogenic compound, which can be determined photometrically at 450 nm.

SPECIMEN COLLECTION AND PREPARATION

1. Blood should be drawn using standard venipuncture techniques and the serum should be separated from the red blood cells as soon as practical. Avoid grossly hemolytic, lipidic or turbid samples.
2. Plasma samples collected in tubes containing EDTA, heparin, or oxalate may interfere with test procedures and should be avoided.

3. Specimens should be capped and may be stored for up to 48 hour at 2-8°C prior to assaying. Specimens held for a longer time can be frozen at -20°C for up to 6 months prior to assay. Thawed samples should be inverted several times to mix prior to testing.

MATERIALS AND COMPONENTS

Materials provided with the test kits

1. Anti-Beta-2 MG antibody coated microtiter plate with 96 wells
2. Sample diluent, 100mL
3. Enzyme conjugate reagent, 22 ml
4. B2MG reference standards, 1 set (liquid), ready to use.
5. TMB Substrate, 12ml
6. Stop Solution, 12ml
7. Wash Buffer Concentrate (50X), 15ml

Materials required but not provided:

1. Precision pipettes and tips, 0.5~10µl, 0.05~0.2ml, 1ml
2. Distilled water
3. Disposable pipet tips
4. Vortex mixer
5. Absorbent paper or paper towel
6. Microtiter plate reader
7. Graph paper

REAGENT PREPARATION

1. All reagents should be brought to room temperature (18-22°C) before use. All reagents should be mixed by gently inverting or swirling prior to use. Do NOT induce foaming.
2. Dilute 1 volume of Wash Buffer Concentrate (50x) with 49 volumes of distilled water. For example, Dilute 15 ml of Wash Buffer (50x) into distilled water to prepare 750 ml of washing buffer (1x). Mix well before use.

ASSAY PROCEDURE

1. Both the samples of patient serum and control serum need to be diluted before use for best results. **Prepare a series of small tubes (such as 1.5 ml microcentrifuge tubes) and mix 10 µl serum with 1.0 ml Sample Diluent (101 fold dilution). Do not dilute the standards; they have already been pre-diluted.**
2. Secure the desired number of coated wells in the holder. Dispense 5µl of B2MG standards, diluted specimens, and diluted controls into appropriate wells. Dispense 200 µl Sample Diluent. Gently mix for 10 seconds. Incubate at 37°C for 30 minutes.
3. Remove the incubation mixture by emptying the plate contents into a waste container. Rinse and empty the microtiter plate 5 times with washing buffer (1X). Strike the microtiter plate sharply onto absorbent paper or paper towels to remove all residual water droplets.
4. Dispense 200µl of enzyme conjugate reagent into each well. Gently mix for 10 seconds Incubate at 37°C for 30 minutes. Remove the contents and wash the plate as described in step 3 above.
5. Dispense 100µl TMB solution into each well. Gently mix for 10 seconds. Incubate at room temperature in the dark for 20 minutes.
6. Stop the reaction by adding 100µl of Stop Solution to each well. Gently mix for 10 seconds. **It is very important to make sure that the blue color changes to yellow color completely.** Read optical density at 450nm with a microtiter plate reader within 15 minutes.

Important Note:

1. The wash procedure is critical. Insufficient washing will result in poor precision and falsely elevated absorbance readings.
2. It is recommended that no more than 32 wells be used for each assay run if manual pipetting is used since pipetting of all standards, specimens and controls should be completed within 5 minutes. A full plate of 96 wells may be used if automated pipetting is available.
3. Duplication of all standards and specimens, although not required, is recommended.


RESULTS

Calculate the mean absorbance value for each set of B2MG reference standards, specimens and controls. Construct a standard curve by plotting the mean absorbance obtained from each reference standard against its concentration in µg per ml on graph paper, with absorbance values on the vertical or Y axis and concentrations on the horizontal or X axis. The best curve fit for the programming analysis is Quadratic. Use the mean absorbance values for each specimen to determine the corresponding concentration of B2MG in µg per mL from the standard curve. It is recommended that samples be analyzed in duplicates. *Since the B2MG standards have already been diluted 101-fold, there is no need for the samples or controls to be multiplied by the dilution factor.*

EXAMPLE OF STANDARD CURVE

Results of typical standard run with optical density reading at 450nm shown in the Y axis against B2MG concentrations shown in the X axis. This standard curve is for the purpose of illustration only, and should not be used to calculate unknowns. Each user should obtain his or her own data and standard curve.

B2MG Values (µg/ml)	Absorbance (450nm)
0	0.040
0.5	0.344
2.0	1.035
5.0	1.930
10.0	2.599
20.0	3.394



EXPECTED VALUES AND SENSITIVITY

Healthy individuals are expected to have B2MG values below 2.0 µg/mL.

PERFORMANCE CHARACTERISTICS

I. Accuracy: Serum Comparison between Our Assay kit and a reference method provide the following data

Range From	0.45	~	16.30
N		=	100
Correlation Coefficient		=	0.9916
Slope		=	1.002
Intercept		=	0.057
Our Mean		=	3.004
Ref. Mean		=	2.941

II. Precision.

1. Intra-Assay

Concentrations	Replicates	Mean	S.D.	% CV
Level I	20	1.05	0.091	8.65%
Level II	20	3.39	0.26	7.60%
Level III	20	8.366	0.3587	4.29%

2. Inter-Assay

Concentration s	Replicates	Mean	S.D.	% CV
Level I	16	1.062	0.0988	9.31%
Level II	16	3.477	0.3108	8.94%
Level III	16	8.443	0.4247	5.03%

III. Linearity

Two patient sera were serially diluted with 0 ng/mL standard in a linearity study. The average recovery was 102.0 %.

Sample A			
Dilution	Expected	Observed	% Recov.
undiluted	14.65	14.65	
2x	7.33	7.01	95.7%
4x	3.66	3.64	99.4%
8x	1.83	1.86	101.6%
16x	0.92	0.96	104.8%
Average Recovery: 100.4%			

Sample B			
Dilution	Expected	Observed	% Recov.
undiluted	12.44	12.44	
2x	6.22	6.32	101.6%
4x	3.11	3.28	105.5%
8x	1.56	1.59	102.3%
16x	0.78	0.82	105.5%
Average Recovery: 103.7 %			

IV. Sensitivity

The sensitivity is defined as the concentration of B2MG that corresponds to the absorbance that is two standard deviations greater than the mean absorbance of 20 replicates of the zero calibrator. The minimum detectable concentration of this assay is estimated to be 0.2 µg/ml.

V. Cross-reactivity

The following cancer marker antigens at high concentrations, as seen in cancer patients, were assayed to determine the possible reactivity.

Antigens	Concentration	Equivalent B2 MG	% Cross-react.
Ferritin	10,000 ng/mL	0.00	0.00
PSA	10,000 ng/mL	0.00	0.00
AFP	10,000 ng/mL	0.00	0.00
CEA	10,000 ng/mL	0.00	0.00
Human IgG	20.0 g/L	0.00	0.00
Bilirubin	0,3 mg/ml	0.00	0.00
Triglycerides	20 mg/ml	0.00	0.00
Hemoglobin	5 mg/ml	0.00	0.00

VII. Hook Effect

No hook effect was observed in this assay.

Stability:

Store at 2°C ~ 8°C, the shelf life of the kits will be 12 months

LIMITATIONS OF PROCEDURE



- Reliable and reproducible results will be obtained when the assay procedure is carried out with a complete understanding of the package insert instructions and with adherence to good laboratory practice.
- The wash procedure is critical. Insufficient washing will result in poor precision and falsely elevated absorbance readings.
- Heterophilic antibodies such as human anti-mouse antibodies (HAMA) are frequently found in the serum of human subjects. Those antibodies can cause severe interference in many immunodiagnostic procedures. This assay has been designed to minimize that kinds of interference. Nevertheless, complete elimination of this interference from all patient specimens cannot be guaranteed. A test result that is inconsistent with the clinical picture and patient history should be interpreted with caution.

STORAGE

Unopened test kits should be stored at 2-8°C upon receipt and the microtiter plate should be kept in a sealed bag with desiccants to minimize exposure to damp air. Opened test kits will remain stable until the expiring date shown, provided it is stored as prescribed above. A microtiter plate reader with a bandwidth of 10nm or less and an optical density range of 0-2 OD or greater at 450nm wavelength is acceptable for use in absorbance measurement.

REFERENCES

- Berggard I and Beam AG: 1968. Isolation and properties of a low molecular weight β₂-globulin occurring in human biological fluids. J Biol Chem 243: 4095-4103.
- Grey HM, Kubo RT, Colon SM, Poulik MD, Cresswell P, Springer T, Turner M and Strominger JL: 1973. The small subunit of HL-A antigens is β₂-microglobulin. J Exp Med 138: 1608-1612.
- Nakamuro K, Tanigaki N and Pressman D: 1973. Multiple common properties of human β₂-microglobulin and the common portion fragment derived from HL-A antigen molecules. Proc Natl Acad Sci 70: 2863-2865.
- Evrin PE and Wibell L: 1972. The serum levels and urinary excretion of β₂-microglobulin in apparently healthy subjects. Scand J Clin Lab Invest 29: 69-74.
- Crisp AJ, Coughlan RJ, Mackintosh D, Clark B and Panayi, GS: 1983. β₂-microglobulin plasma levels reflect disease activity in rheumatoid arthritis. J Rheumatol 10: 954-956.

<p>ISO 13485 ISO 9001</p> 			
 <p>Diagnostic Automation/ Cortez Diagnostics, Inc. 23961 Craftsman Road, Suite E/F, Calabasas, California 91302 USA</p>			
Date Adopted	Cat # 4200-16		
2008-05-04	AccuDiag™- B2-Microglobulin ELISA -2014		
<table border="1"> <tr> <td>EC</td> <td>REP</td> </tr> </table>	EC	REP	<p>CEpartner4U, Esdoornlaan 13, 3951DB Maarn. The Netherlands. www.cepartner4u.eu</p>
EC	REP		
Revision B Date: 02-04-2014			